Dinah Weissmann
ALCEDIAG, France
Biography
Dinah Weissmann is an Executive Vice President at ALCEDIAG’s, biotech company dedicated to the development of innovative diagnostics based on epigenetic biomarkers mainly RNA editing. She is also Co-director of a public private laboratory, Sys2Diag that was created in 2015 and dedicated to the understanding of molecular basis of complex diseases. Her research fields are mainly in neuroscience which leads to the discovery of a specific plasticity in adult brain coined phenotype plasticity that gave rise to a novel class of antidepressant drugs. Later on, she focused on epigenetic mechanism understanding and developed new tests for diagnosis and management of psychiatric patients as well as prediction of psychiatric adverse effects. She has 15 years of research experience as Director of Research at the CNRS (French academic research institute) and has worked at various leader positions in pharma and biotech companies.
Abstract
Abstract : Epitranscriptomic blood biomarkers to manage psychiatric disorders